- Oops!Something went wrong.Please try again later.
What happened Shares of drugmaker Novavax (NASDAQ: NVAX) are up to the tune of 18.9% as of 2:11 p.m. ET Friday, according to data from S&P Global Market Intelligence, thanks to a confluence of events that work in the company's favor.
Fight back against inflation. This is how Dalio does it.
Shares of Iovance Biotherapeutics (NASDAQ: IOVA) are down 53% as of 12:24 p.m. ET Friday, according to data from S&P Global Market Intelligence, following the release of disappointing results from a pivotal melanoma drug trial released Thursday evening. Iovance had already reported solid results for melanoma treatment Lifileucel in the middle of last year, ultimately finding a response rate of 36%. This follow-on study of cancer patients with advanced melanoma who had shown improvement after previously receiving and responding to anti-PD-1/L1 therapies isn't as encouraging, with an objective response rate of only 29%.
Theme parks, streaming services, and multiplexes are hoping the next few months are lucrative, and Walt Disney (NYSE: DIS), Netflix (NASDAQ: NFLX), and AMC Entertainment Holdings (NYSE: AMC) feel that there is no time like the present. A popular series is back with a new season -- part of a new season, anyway -- on Netflix. AMC hopes that the reboot of a classic action franchise will kick off a promising summer season.
Despite all the attention that renewable energy companies get, having operations in the renewable energy space alone does not make a stock a buy. In fact, several renewable energy companies are struggling just to stay profitable. Let's discuss two renewable energy stocks that look attractive right now, and one that's best avoided.
Shares of Moderna (NASDAQ: MRNA) were jumping 7.5% higher as of 11:30 a.m. ET on Friday. Instead, Moderna appears to be benefiting from the overall stock market bounce. Good news for the overall stock market tends to be good news for Moderna.
Mirati is unlikely to carve out a share of the lung cancer market, analysts said Friday as MRTX stock collapsed on a testing disappointment.
Shareholders in Amazon (NASDAQ: AMZN) beat a rising market on Friday morning, with shares gaining 3% by 10:45 a.m. ET compared to a 1.4% boost in the S&P 500. The rally was powered by a brightening outlook around economic growth and consumer spending. A major factor driving Amazon's stock higher on Friday was the boost in the wider tech world.
Stop investing in mediocre businesses. Buy the best, instead.
Shares of Dutch Bros (NYSE: BROS) are rocketing higher this week, surging 34.1% compared to where they closed last Friday, according to data from S&P Global Market Intelligence, riding a meme stock wave of buying. After it was reported that short interest in the coffee shop shot up almost 30% in the latest period, stock traders who populate various internet stock chat rooms piled into the stock. Meme stocks, of course, are stocks that trade more on social media chatter than on business fundamentals, though in Dutch Bros' case the underlying business is pretty good, too.
In this article, we discuss the 10 stocks that Jim Cramer and hedge funds agree on. If you want to read about some more stocks that Jim Cramer and hedge funds agree on, go directly to Jim Cramer and Hedge Funds Agree on These 5 Stocks. In the past few weeks, Jim Cramer, the journalist […]
Shares of Farfetch Limited (NYSE: FTCH), a luxury fashion e-commerce platform, spiked today after the company reported a better-than-expected loss in the first quarter. Farfetch reported an adjusted loss per share of $0.24 in the first quarter, which was down from a loss of $0.22 per share in the year-ago quarter but ahead of analysts' average estimate of a loss of $0.28 per share. "Our core business remains very strong, in spite of the macro events in China and ceasing operations in Russia, which impacted our performance and outlook," José Neves, Farfetch's founder and CEO, said in a press release.
In this article, we will look at 10 undervalued stocks to buy according to billionaire Leon Cooperman. If you want to skip reading about Leon Cooperman’s early life, investment philosophy, and his hedge fund’s performance, you can go directly to 5 Undervalued Stocks to Buy According to Billionaire Leon Cooperman. Leon Cooperman is an American […]
Novavax (NASDAQ: NVAX) is very late to the party in entering the COVID-19 vaccine market. Wall Street analysts are extremely pessimistic about the stock. Novavax definitely is late in entering the COVID-19 vaccine market and still hasn't won authorization for its vaccine in the U.S. Novavax's shares really have sunk like a brick since the fourth quarter of 2021.
The cannabis company's per-share loss was almost five times as big as analysts had expected. The stock plunged in response.
Risk and reward are the yin and yang of stock trading, the two opposite but essential ingredients in every market success. And there are no stocks that better embody both sides – the risk factors and the reward potentials – than penny stocks. These equities, priced below $5 per share, typically offer high upside potentials. Even a small gain in share price – just a few cents – quickly translates into a high yield return. Of course, the risk is real, too; not every penny stock is going to show th
If you have $77,280 that you can afford to invest, these stocks can turn that into $400 in recurring monthly income.
Most of the recent discussion of student debt has focused on the prospect of forgiving that debt—telling borrowers that they don’t have to repay the funds the federal government provided to help them pay for college or graduate school. The fierce debates about the pros and cons of such a policy rarely focus on the advantages of extending credit to students or on what debt forgiveness today would mean for students borrowing tomorrow, next year, and for the foreseeable future. Should President Biden cancel outstanding student debt, it would not relieve students from reliance on borrowing in the future.
Choosing between two depends on whether you'd rather pay taxes now, or later.
The White House on Thursday announced more steps to make the antiviral treatment Paxlovid more accessible across the U.S., cautioning that COVID-19 cases are likely to continue to climb over the summer travel season.